(HealthDay)—A genetic variant associated with weight loss after Roux-en-Y gastric bypass (RYGB) surgery has been identified, according to a study published in the May 2 issue of the American Journal of ...
Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.
(HealthDay)—A new class of sleep medications appears to help people fall asleep without causing grogginess the next day, researchers say.
The U.S. Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.
(HealthDay)—For patients with preexisting occlusive vascular disease, the combination of niacin and the anti-flushing agent laropiprant provides no benefit and is associated with an increase in serious ...
A combination drug containing niacin failed to lower the risk of heart attacks or strokes and even proved harmful for some with vascular disease, a study released Saturday reported.
Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
Merck & Co.'s fourth-quarter profit fell 7 percent because of hits from generic competition and one-time charges, and the company pushed back plans to seek approval of a key experimental osteoporosis drug.
(HealthDay)—The drug Oxytrol has been approved by the U.S. Food and Drug Administration as the first over-the-counter treatment for women 18 and older with overactive bladder.
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.
Drugmaker Merck says it is suspending its sale of the cholesterol drug Tredaptive and is telling doctors to quit prescribing the medicine.
(HealthDay)—Much of the genetic risk for colorectal cancer (CRC) in the general population is mediated by differential adenoma risk, according to research published in the January issue of Gastroenterology.
Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.
German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
For Alzheimer's patients and their families, desperate for an effective treatment for the epidemic disease, there's hope from new studies starting up and insights from recent ones that didn't quite pan out.